ELN 2022 recommends screening for over ten molecular genetic markers in all newly diagnosed AML patients, including FLT3, NPM1, CEBPA, RUNX1, TP53, and others, and several gene fusions (PML::RARA, CBFB::MYH11, RUNX1::RUNX1T1, BCR::ABL1, and KMT2A rearrangements), in addition to CCA. This evidence concerns the gene FLT3 and acute myeloid leukemia.